A Case of Type I Hepatorenal Syndrome Treated with Vasopressin
- 1 Department of Internal Medicine, Lankenau Medical Center, Wynnewood, USA
- 2 Department of Nephrology, Lankenau Medical Center, Wynnewood, USA
Abstract
Hepatorenal syndrome (HRS) is a grave complication of end-stage liver disease and is associated with a very high mor tality. This case report describe d a 42-year-old female with advanced alcohol-induced cirrhosis who developed HRS that was initially treated with Midodrine and Octreotide but renal function continued to deteriorate. Vasopressin therapy was added and HRS was successfully reversed. There are few data available on the use of vasopressin for HRS and this case supports its use in treatment of HRS, particularly in countries where the more widely studied Terlipressin is un available. This case also demonstrates that a patient failing one medical therapy for HRS may respond to an alternative or adjunctive therapy . Therefore , this should be attempted to increase the patient’s chance of survival.
- C. Alessandria, A. Ottobrelli, W. Debernardi-Venon, L. Todros, M. T. Cerenzia, S. Martini, et al., “Noradrenalin vs Terlipressin in Patients with Hepatorenal Syndrome: A Prospective, Randomized, Unblinded, Pilot Study,” Journal of Hepatology, Vol. 47, No. 4, 2007, pp. 499-505. doi:10.1016/j.jhep.2007.04.010
- S. J. Munozo, “The Hepatorenal Syndrome,” Medical Clinics of North America, Vol. 92, No. 4, 2008, pp. 813-837. doi:10.1016/j.mcna.2008.03.007
- T. H. Kiser, R. Maclaren and D. N. Fish, “Treatment of Hepatorenal Syndrome,” Pharmacotherapy, Vol. 29, No. 10, 2009, pp. 1196-1211. doi:10.1592/phco.29.10.1196
- P. Angeli, R. Volpin, G. Gerunda, R. Craighero, P. Roner, R. Merenda, et al., “Reversal of Type 1 Hepatorenal Syndrome with the Administration of Midodrine and Octreotide,” Hepatology, Vol. 29, No. 6, 1999, pp. 1690-1697. doi:10.1002/hep.510290629
- E. Esrailian, E. R. Pantangco, N. L Kyulo, K. Q. Hu and B. A. Runyon, “Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome,” Digestive Diseases and Sciences, Vol. 52, No. 3, 2007, pp. 742-748. doi:10.1007/s10620-006-9312-0
- G. Pomier-Layragues, S. C. Paquin, Z. Hassoun, M. Lafortune and A. Tran, “Octreotide in Hepatorenal Syndrome: A Ransomized Double-Blind, Placebo-Controlled, Corssover Study,” Hepatology, Vol. 38, No. 1, 2003, pp. 238-243. doi:10.1053/jhep.2003.50276
- R. Moreau, F. Durand, T. Poynard, C. Duhamel, J. P. Cervoni, P. Ichai, et al., “Terlipressin in Patients with Cirrhosis and Type 1 Hepatorenal Syndrome: A Retroepsctive Mulitcenter Study,” Gastroenterology, Vol. 122, No. 4, 2002, pp. 923-930. doi:10.1053/gast.2002.32364
- C. Halimi, P. Bonnard, D. Bernard, P. Mathurin, A. Mofredj, V. Martino, et al., “Effect of Terlipressin (Glypressin) on Hepatorenal Syndrome in Cirrhotic Patients: Results of a Multicentre Pilot Study,” European Journal of Gastroenterology & Hepatology, Vol. 14, No. 2, 2002, pp. 153-158. doi:10.1097/00042737-200202000-00009
- A. J. Sanyal, T. Boyer, G. Garcia-Tsao, F. Regenstein, L. Rossaro, B. Appenrodt, et al., “A Randomized, Prospective, Double-Blind, Placebo-Controlled, Trial of Terlipressin for Type 1 Hepatorenal Syndrome,” Gastroenterology, Vol. 143, No. 5, 2008, pp. 1360-1368. doi:10.1053/j.gastro.2008.02.014
- P. Solanki, A. Chawla, R. Garg, R. Gupta, M. Jain and S. K. Sarin, “Beneficial Effects of Terlipressin in Hepatorenal Syndrome: A Prospective, Randomized PlaceboControlled Clinical Trial,” Journal of Gastroenterology Hepatology, Vol. 18, No. 2, 2003, pp. 152-156. doi:10.1046/j.1440-1746.2003.02934.x